InsideTSCA | As Virus Continues, Concerns Rise over Risks from Disinfectant Use

Whether your products are used for medical purposes or used in homes and offices, our Food, Drug & Device/FDA and Environment, Land Use & Natural Resources teams highlight the key regulatory requirements that apply, what has changed, and what the FDA and EPA will be watching out for when products are marketed for use in the evolving coronavirus (COVID-19) pandemic. 

Alston & Bird has formed a working group to advise clients on the business and legal implications of the COVID-19 coronavirus.

Whatever the results of this presidential election, or any presidential transition, most government workers will continue to do the same work in the same way. In this article, Kevin Minoli draws upon his 18 years at the U.S. Environmental Protection Agency and takes a look at the COVID-19-related work of the EPA Office of Pesticide Programs as an example of an agency office that will continue to deliver results regardless of who wins on Nov. 3, 2020.

Our Environment, Land Use & Natural Resources Group explains how companies can benefit from the Environmental Protection Agency’s new interim guidance expediting the product registration process for long-lasting antimicrobial products effective against the COVID-19 coronavirus. 

Senate GOP proposes $1 trillion COVID-19 relief bill, CDC releases PSAs on convalescent plasma, and U.S. Postal Service and Treasury agree to $10 Billion CARES Act loan. Read about these and other actions in today’s Alston & Bird Coronavirus Flash Update.